



(11) **EP 2 944 310 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 72

(51) Int Cl.:
A61K 31/423 ^(2006.01) **A61P 11/00** ^(2006.01)

(48) Corrigendum issued on:
09.03.2016 Bulletin 2016/10

(43) Date of publication:
18.11.2015 Bulletin 2015/47

(21) Application number: **14168742.6**

(22) Date of filing: **16.05.2014**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME


(71) Applicants:
• **Mifcare**
75014 Paris (FR)
• **Institut National de la Santé et de la**
Recherche Médicale (INSERM)
75654 Paris Cedex 13 (FR)

(72) Inventors:
• **GUIGNABERT, Christophe**
94110 Arcueil (FR)
• **LE HIRESS, Morane**
94700 Maisons-Alfort (FR)
• **TU, Ly**
94200 Ivry-sur-Seine (FR)
• **JALCE, Gaël**
91240 Saint-Michel-sur-Orge (FR)
• **AKAGAH, Bernardin**
91300 Massy (FR)

(74) Representative: **Icosa**
83 avenue Denfert-Rochereau
75014 Paris (FR)

(54) **MIF inhibitors for the acute or chronic treatment of pulmonary hypertension**

(57) The present invention relates to the use of compounds of general formula I:



and pharmaceutically acceptable enantiomers, salts or solvates thereof, for treating pulmonary hypertension in a subject.

EP 2 944 310 A8